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INTRODUCTION
Idiopathic thrombocytopenic purpura (ITP) is a disorder
characterized by thrombocytopenia with a shortened platelet
survival, normal to increased numbers of bone marrow
megakaryocytes, and elevated levels of platelet-associated
IgG (1, 2). Autoantibodies directed against platelet mem-
brane glycoprotein and that lead to platelet destruction
form the leading cause of ITP.
Helicobacter pylori has been considered a central etiologic
agent for gastritis, peptic ulcer, and gastric adenocarcinoma
for many years (3, 4). H. pylori infection has also been impli-
cated in the pathogenesis of non-digestive diseases, such as
vascular disease (coronary heart disease), autoimmune diseases
(rheumatoid arthritis, Sjogren’s syndrome, autoimmune thy-
roid diseases, and Henoch-Schonlein purpura), and certain
skin diseases (chronic urticaria and rosacea) (5-7).
Recently, it has been suggested that H. pylori may con-
tribute to the pathogenesis of ITP (8-14). Even though H.
pylori eradication therapy has been shown to be effective in
some studies (9-15), results have been inconsistent from
study to study, and the pathogenetic mechanisms of H. pylori-
associated ITP remain elusive. In one study, patients had a
very low likelihood of effectiveness, and a response was seen
3 months after treatment (16). However, it should be noted
that serious complications such as bleeding could happen
within this 3-month period.
Therapy options for H. pylori-associated ITP may include
both eradication therapy and classical therapy for ITP. Pred-
nisolone is the drug of choice, but cyclophosphamide and
vincristine have also been shown to be effective immunosup-
pressive agents in classic ITP therapy (17-19). Therefore, we
hypothesized that adding immunosuppressive agents to erad-
ication therapy would maximize the therapeutic effect. The
purpose of this study was to assess the efficacy of H. pylori
eradication therapy combined with immunosuppressive ther-
apy.
MATERIALS AND METHODS
Patients
Between January 2003 and January 2006, 34 consecutive
adult patients with chronic ITP were investigated in this
study. The usual-first line therapy in patients with bleeding
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Outcome of Immunosuppressive Therapy with Helicobacter pylori
Eradication Therapy in Patients with Chronic Idiopathic 
Thrombocytopenic Purpura
We initiated this study to investigate whether combining Helicobacter pylori eradi-
cation with immunosuppressive therapy provides an additional benefit to patients
with idiopathic thrombocytopenic purpura (ITP) that has relapsed or has not respond-
ed to steroid and/or danazol therapy in patients who have H. pylori infection. Thir-
ty-four patients with chronic ITP that had relapsed or failed to steroid and/or dana-
zol therapy were assessed for H. pylori infection. Of the 21 confirmed cases, 12
patients were given H. pylori eradication therapy alone (EA), while 9 patients receiv-
ed eradication therapy combined with immunosuppressive therapy (EI). The response
rate was not significantly different between patients in the EA and those in the EI
group (41.7% in the EA group vs. 66.7% in the EI group, p=0.345). The median
platelet count at 6 months after therapy was higher in the EI group patients (75×
10
9/L in the EI group patients vs. 18×10
9/L in the EA group patients, p=0.028).
The median response duration was also longer in the EI group patients (9 months
in the EI group patients vs. 3 months in the EA group patients, p=0.049). These
results show that a significant benefit is gained by the use of H. pylori eradication
combined with immunosuppressive therapy over the use of eradication therapy
alone for patients with chronic ITP.
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. .tendency and a low platelet count is treatment with pred-
nisolone at a dose of 1 mg/kg/day.
Patients who had platelet counts of less than 30×109/L
at least 3-6 months after steroid therapy were candidates for
danazol and/or vincristine therapy. Patients with gum bleeding
or a platelet count of less than 20×109/L while undergoing
the above therapy received intravenous immunoglobulin
therapy or platelet transfusion. Thirty-four patients with no
response to this treatment schedule were enrolled to the
present study. The diagnosis of ITP was made according to
the criteria set forth by the American Society of Hematolo-
gy (ASH) guidelines (8)-based thrombocytopenia unrelated
to any underlying viral infection, collagen vascular disease,
malignancy or medication. Patients were considered elligible
if they presented during an acute initial or recurrent episodes
of ITP, such that platelet counts did not increase to a safe level
despite treatment with multiple modalities or if chronic ITP
could not be managed with acceptable doses of corticosteroids.
This retrospective study was reviewed and approved by
our institutional review board.
Response criteria
The clinical response to treatment was defined as follows.
Complete response (CR) was defined as normalization of the
platelet count (≥150×109/L) for more than 2 months with
or without maintenance therapy. Partial response (PR) was
defined as a platelet count between 50×109/L and 150×
109/L for more than 2 months or when the platelet count
increased above 50% compared to the pretreatment level
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Patient
No.
Sex/age
Disease
duration
(months)
Diagnosis of
H. pylori
infection
*Post-count
(×10
9/L)
Response
Time to
response
(months)
Response
duration
(months)
Initial platelet
(×10
9/L)
1EI F/24 42 IgG, CLO 22 76 PR 5 13
2EI F/66 32 IgG, UBT 2 35 NR --
3EI M/44 12 IgG, CLO 20 67 PR 1 5
4EI M/29 58 IgG, CLO 7 34 NR --
5EI F/26 29 IgG, CLO 11 75 PR 2 29
6EI M/31 38 CLO 7 33 NR --
7EI F/46 39 IgG, UBT 1 106 PR 2 25
8EI M/61 18 IgG, CLO 16 185 CR 1 9
9EI F/70 24 IgG, CLO 26 140 PR 2 10
10EA M/51 61 IgG, UBT 12 9 NR --
11EA F/26 28 IgG, CLO 19 142 PR 3 3
12EA F/41 73 IgG, UBT 13 35 PR 1 3
13EA F/46 103 CLO 9 32 PR 3 8
14EA F/42 73 IgG, UBT 2 8 NR --
15EA F/51 100 IgG, UBT 27 8 NR --
16EA M/21 68 IgG, CLO 21 13 NR --
17EA F/48 99 UBT 2 18 NR --
18EA F/49 87 UBT 25 101 PR 2 24
19EA F/48 87 IgG, CLO 29 18 NR --
20EA F/45 62 UBT 10 18 NR --
21EA F/19 38 CLO 22 121 CR 2 9
22 IA F/57 68 CLO 3 157 CR 1 12
23 IA F/53 58 IgG, UBT 14 18 NR --
24 IA F/54 60 IgG, UBT 3 8 NR --
25 IA F/46 69 CLO 8 4 NR --
26 IA F/47 60 IgG, UBT 16 98 PR 1 8
27 IA F/33 39 CLO 12 258 CR 1 12
28 IA F/80 36 IgG, UBT 23 18 NR --
29 IA F/59 26 CLO 16 6 NR --
30 IA M/27 14 IgG, UBT 29 20 NR --
31 IA F/39 60 IgG, UBT 29 14 NR --
32 IA F/71 70 IgG, UBT 27 24 NR --
33 IA F/34 70 CLO 26 9 NR --
34 IA F/78 71 IgG, UBT 11 27 NR --
Table 1. Clinical data and response to therapy in the patients 
*Maximum platelet count after therapy was started.
IgG, Helicobacter pylori IgG; CLO, rapid urease test; UBT, 
13C-urea breath test; EI, eradication therapy combined with immunosuppressive therapy;
EA, H. pylori eradication therapy alone; CR, complete response; PR, partial respons; NR, no response; IA, immunosuppressive therapy alone; VA,
vincristine; IVIG, intravenous immune globulin.with or without maintenance therapy. No response (NR) is
defined as a platelet count below 50×109/L or when the
platelet count did not increase to more than 50% of the
pretreatment level with or without maintenance therapy.
Diagnosis of H. pylori infection
All patients were screened for H. pylori infection using a
13C-urea breath test (UBT), serum H. pylori immunoglobu-
lin G, or a rapid urease test (CLO test) by an endoscopic biop-
sy (Table 1).
Treatment
H. pylori infection was treated with standard eradication
therapy. For H. pylori-positive patients, therapy consisted of
amoxicillin 1,000 mg, clarithromycin 500 mg, and a proton
pump inhibitor (esomeprazole) 40 mg taken together twice
a day for 2 weeks.
Cycles of immunosuppressive therapy were repeated every
3 weeks. Patients were treated with an immunosuppressive
therapy consisting of oral cyclophosphamide (150 mg/m2/day
taken orally on days 1 to 5 every 3 weeks), vincristine (1.4
mg/m2 taken intravenously on day 1 every 3 weeks), and pred-
nisolone (40 mg/m2taken orally on days 1 to 5 every 3 weeks)
with a maximum of 6 cycles of therapy. 
All of the 21 H. pylori-positive patients were treated with
eradication therapy for 2 weeks, and 9 of the 21 patients were
treated with additional immunosuppressive therapy imme-
diately after receiving the eradication therapy. Monitoring
of bacterial eradication using the UBT was performed at 3
months after the eradication therapy. H. pylori-negative patients
received immunosuppressive therapy alone with the same
schedule (Fig. 1).
Monitoring
Eradication or persistence of H. pylori was assessed after 3
months of eradication therapy using a UBT. The platelet
count was assessed every week for a month and then on a
monthly basis.
Statistical analysis
Numerical data were compared with the use of the Kruskal-
Wallis H test and the Mann-Whitney U test for indepen-
dent samples. Differences were considered to be statistically
significant at a level of p<0.05. The event-free-response dura-
tion was assessed using the Kaplan-Meier method and com-
pared between risk groups using the log-rank test. An event
was defined as a platelet count below 20×109/L after initial
response had been achieved. Data were analyzed using the
Statistical Software Package for the Social Sciences (SPSS
version 12.0 for Windows).
RESULTS
Patients
Of the 34 adult ITP patients, 7 were male and 27 were
female; the median age was 45 yr (range, 19 to 70 yr). The
median disease duration was 58 months (range, 12-103
months), and the median platelet count was 13.5×109/L
(range, 1-29×109/L). All of the 34 patients were treated
previously with steroid, danazol, and/or vincristine therapy.
All of the patients transiently responded to steroid treatment
for about 2 months, but relapsed. After relapse, all of the
patients were treated with danazol and/or vincristine thera-
py, but without a durable response. H. pylori infection was
confirmed in 21 of the 34 (61.7%) patients (Table 1).
H. pylori-positive patients
The 21 H. pylori-positive patients received eradication
therapy alone (EA) or eradication therapy combined with
immunosuppression (EI) according to the preference of the
physicians. The median disease duration before eradication
therapy was 73 months for patients in the EA group and 32
months for patients in the EI group. The initial mean platelet
count was 15.5×109/L (range, 2-29×109/L) for patients in
the EA group and 11×109/L (range, 126×109/L) for patients
in the EI group. The median durations of previous steroid,
danazol, and vincristine therapy were 4, 4.5, and 3.5 months
for patients in the EA group, respectively, and 4, 4, and 3
months for patients in the EI group, respectively. The types
of drugs used for treatment including steroid, danazol, and
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Chronic ITP patients with relapse or failed steroid/danazol therapy
Diagnosis of H. pylori infection (34)
H. pylori-positive patients (21)
Eradication alone (2 weeks)
Lab follow-up
(12, EA group)
IST (6 cycles, 18 weeks)
(9, EI group)
UBT for eradication monitoring
(3 months after eradication therapy)
Follow-up of serial platelet counts (34)
IST (6 cycle, 18 weeks)
(13, IA group)
H. pylori-negative patients (13)
Fig. 1. Flow-chart of treatment indicating the three schedules for
chronic ITP patients.
Round braskets, number of patients and treatment duration; EA,
eradication alone; EI, eradication combined with immunosuppres-
sive therapy; IA, immunosuppressive therapy alone.vincristine were not different between patients in the two
groups. The demographic composition of the two groups
was well balanced (Table 2).
H. pylori-negative patients
The 13 H. pylori-negative patients were treated with im-
munosuppressive therapy alone (IA) and compared with the
H. pylori-positive EI group of patients to evaluate the useful-
ness of eradication therapy. The median age was 53 yr and
median disease durations before treatment was 60 months.
The initial mean platelet count were 16×109/L (range, 2-
29×109/L). The median durations of previous steroid, dana-
zol and vincristine therapy were 4, 4, and 3 months for pati-
ents in the IA group (Table 2). The characteristics of the pati-
ents were not different from those of the H. pylori-positive
patients.
Comparison of treatment response
In comparison of the EA and EI groups of patients, the time
to response did not show a statistically significant difference.
To investigate the predictive value of the response to treat-
ment for the H. pylori-positive patients, several parameters
including the mean platelet count at 6 months after treat-
ment, the response duration, and the response rate were com-
pared between the EA and EI groups of patients. The median
platelet count at 6 months after treatment was 75×109/L
for the EI group of patients compared with 18×109/L for
the EA group of patients (p=0.028). The median response
duration was 9 months for the EI group of patients, com-
pared with 3 months for the EA group patients (p=0.049).
Five patients (41.7%) in the EA group achieved a response
(CR in one and PR in four patients), while 6 patients (66.7
%) in the EI group also achieved a response (CR in one and
PR in five patients). The response rate was not significantly
different between the two groups (p=0.345) (Table 3).
Whether or not, H. pylori infection affects the pathogene-
sis of ITP and eradication results in a beneficial effect, the
efficacy of treatment was compared between H. pylori-posi-
tive patients (EI group) and H. pylori-negative patients (IA
group). The response rate for the two groups was not signif-
icantly different (p=0.096). The EI group of patients showed
a higher median platelet count at 6 months after treatment
(75×109/L for patients in the EI group and 18×109/L for
patients in the EA group) and the median response duration
(9 months for patients in the EI group and 3 months for
448 M.-K. Song, J.-S. Chung, H.-J. Shin, et al.
Eradication 
therapy alone 
(EA group)
Combined 
therapy
(EI group)
H. pylori-
negative
patients 
(IA group)
p
value
Total number 12 9 13 -
Median age,  45.5 (19-51) 44 (24-70) 53 (27-80) 0.274
yr (range)
Median disease  73 32  60 0.072
duration, months (28-103) (12-58) (14-71)
(range)
Median initial  15.5 11  16  0.597
platelet count, (2-29) (1-26) (2-29)
×10
9/L (range)
Median duration of previous treatment, months (range)
Steroid 4 (4-5) 4 (3-5) 4 (3-5) 0.380
Danazol 4.5 (0-5) 4 (0-5) 4 (0-4) 0.053
Vincristine  3.5 (0-4) 3 (0-4) 3 (0-4) 0.877
monotherapy
Table 2. Characteristics of the patients
EA, H. pylori eradication therapy alone; EI, eradication therapy com-
bined with immunosuppressive therapy; IA, immunosuppressive thera-
py alone.
Eradication
therapy alone
(EA group)
Combined
therapy
(EI group)
p
value
Median time to response,  2 (0-5) 1 (0-3) 0.464
months (range)
Median platelet count after  18 75 0.028
6 months, ×10
9/L (range) (8-142) (33-185)
Response (%)
CR 1 (8.4) 1 (11.1)
PR 4 (33.4) 5 (55.5)
NR 7 (58.3) 3 (33.3)
Total 41.7% 66.7% 0.345
Median response duration,  3 (0-24) 9 (2-29) 0.049
months (range)
Table 3. Comparative results between H. pylori eradication ther-
apy and immunosuppressive therapy of the patients
EA, H. pylori eradication therapy alone; EI, eradication therapy com-
bined with immunosuppressive therapy; CR, complete response; PR,
partial response; NR, no response.
H. pylori-
positive
(EI group)
H. pylori-
negative
(IA group)
p
value
Median platelet count after 6 months,  75 18 0.017
×10
9/L (range) (33-185) (4-258)
Response (%)
CR 1 (11.1) 2 (15.4)
PR 5 (55.5) 1 (7.69)
NR 3 (33.3) 10 (76.9)
Total 66.7% 23.1% 0.096
Median response duration,  3 (0-24) 1 (0-12) 0.003
months (range)
Table 4. Comparable results of immunosuppressive therapy
between H. pylori -positive and -negative patients
EI, eradication therapy combined with immunosuppressive therapy; IA,
immunosuppressive therapy alone; CR, complete response; PR, partial
response; NR, no response.patients in the EA group) was higher in the EI group than
in the EA group (p=0.017 and 0.003, respectively). Three pati-
ents (23.1%) in the IA group achieved a confirmed response
(CR in two and PR in one). The response rate was not signifi-
cantly different between the EI and IA groups (Table 4).
In a comprehensive evaluation, the serial platelet counts for
patients in the EI group were highest among the three groups
(Fig. 2). The median 2-yr response duration rates of the EI,
EA, and IA groups were 66.7%, 41.7%, and 23.1%, respec-
tively. However, the response duration was longer in the EI
group of patients than in the other two groups (p=0.0143)
(Fig. 3).
DISCUSSION
Recently, several studies have demonstrated that patients
with ITP could demonstrate an increase in the platelet count
after eradication of H. pylori infection (9-15). These results
support the hypothesis that an H. pylori-associated variant
can be identified among ITP patients. However, the results
of other studies have failed to either demonstrate a signifi-
cant improvement in the platelet counts after eradication of
H. pylori infection or achieve a significant long-term bene-
fit. Therefore, the pathogenetic mechanisms of H. pylori-
associated thrombocytopenia remain elusive.
Recent studies in Italian and Japanese populations have
suggested that H. pylori could induce ITP (8-14). This patho-
genesis suggests that ITP is related to H. pylori infection
due to an increased mutual coincidence of H. pylori and ITP
in these groups versus the general population. This theory
was strengthened by tests showing improvement in ITP by
H. pylori eradication.
Takahashi et al. (20) reinforced the hypothesis of the link
between H. pylori and ITP by showing that platelet-associ-
ated immunoglobulin can cross-react with the CagA pro-
tein. Franceschi and colleagues (9) contributed follow-up data
from 8 reported ITP patients and showed the disappearance
of anti-CagA antibodies in all 8 platelet responders whose
H. pylori had been eradicated. These results suggest that the
molecular mimicry between H. pylori CagA protein and a
platelet antigen may mediate the autoimmunity in ITP pati-
ents. However, the CagA positivity of H. pylori varies accord-
ing to the geographic location of the patients. In Japan, most
H. pylori strains express CagA, whereas the population of
CagA-positive strains in Western countries is lower (21).
Furthermore, the amino-acid sequence of the H. pylori CagA
protein is known to show a significant diversity among the
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Fig. 2. Distribution of serial platelet counts after treatment. Changes
in the absolute value and median value at differential time points
were measured. Serial platelet counts after therapy in the EI group
(A), in the EA group (B) and in the IA group (C).      , Median platelet
count at each time point.
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Fig. 3. Response duration according to therapeutic setting of ITP.
The response duration was longer in the EI group than the other
two groups (p=0.0143).
EA, eradication alone; EI, eradication combined with immunosup-
pressive therapy; IA, immunosuppressive therapy alone.
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p=0.0143East Asian and Western strains (22).
Another theory suggests that the expression of various
Lewis (Le) antigens by H. pylori isolates and the subsequent
production of anti-Le antibodies could play a role in ITP
pathogenesis as platelets may absorb Lewis antigens from
the serum (23). However, it is uncommon to achieve long-
term benefits from the eradication of H. pylori, and several
studies have shown a difficulty in demonstrating its efficacy
(16, 24).
In the present study, unfortunately, the response duration
in the EA group of patients was 2 months. Moreover, some
patients in the EA group showed no response and almost all
of them who showed a response eventually relapsed.
Eradication therapy for H. pylori-positive patients is acknowl-
edged as being effective to some degree. In this study, com-
parative results in the EI and IA groups of patients showed
that H. pylori eradication was likely to have a beneficial effect
for ITP patients with an H. pylori infection. If the H. pylori
infection did not affect ITP, the results would be similar in
both groups of patients. However, disappointing results
were shown for the EA group of patients compared to the EI
group of patients. Therefore, we are sure that the pathogene-
sis of H. pylori-associated ITP is related not only to H. pylori
infection but also to other concurrent mechanisms, includ-
ing the pathogenesis of classic ITP. Therefore, the manage-
ment of ITP associated with H. pylori infection is complex
and may require additional immunosuppressive therapy.
Cyclophosphamide and vincristine are effective agents for
the treatment of ITP. Figueroa et al. (17) recently reported
responses in 8 out of 10 severely affected, highly refractory
ITP patients treated with cyclophosphamide-based combined
immunosuppressive therapy. In the present study, cyclophos-
phamide, vincristine, and prednisolone (CVP) were all admin-
istered to ITP patients who had failed to show a response
from steroid therapy. Oral cyclophosphamide was given at a
low dose since a high dosage is associated with greater degrees
of drug-induced toxicity and lower patient compliance. Oral
prednisolone was re-applied in an immunosuppressive regi-
men due to the synergistic effect when combined with other
immunosuppressive agents. H. pylori eradication, both with
and without immunosuppressive therapy, was performed,
with superior results for the EI group of patients. The platelet
count at 6 months after the initial treatment was higher in
the EI group of patients than in the EA group of patients,
while a longer response duration was achieved in the same
group (Table 3).
The efficacy of immunosuppressive therapy in H. pylori-
negative patients was evaluated to determine whether the
results for the EI group of patients is the synergistic effect of
the two-treatment arms or only the effect of the immuno-
suppressive therapy, regardless of eradication. The median
platelet count at 6 months after treatment and the response
duration were both superior in the EI group of patients than
in the IA group of patients (Table 4). Both immunosuppres-
sive therapy and eradication had a just limited effectiveness
if used alone.
In this study, the effect of eradication alone therapy and
eradication combined with immunosuppressive therapy was
not compared, as all the H. pylori-positive patients received
eradication therapy. Although the EI group did not show a
superior response rate, the group achieved a longer response
duration than the others. Therefore, in our opinion, there is
insufficient evidence to include only eradication for ITP patients
having an H. pylori infection.
CVP therapy is usually used for chronic ITP (17-19). How-
ever, because combination immunosuppressive therapy em-
ploys anticancer drugs, adverse risks including leukomogenic
potential, teratogenicity, and sterility must be considered,
especially when these drugs are used for patients with non-
malignant diseases. The most important side effect is sec-
ondary malignancy, particular acute leukemia. In patients
with rheumatologic disorders or ITP treated with oral cyclo-
phosphamide, the risk appears to be related to the cumula-
tive cyclophosphamide dose and duration of therapy (25, 26).
However, although a low cumulative dose of oral cyclophos-
phamide was administered during a short duration in this
study than in previous studies, it did not show any remark-
able adverse effects in this study.
Although a careful weighing of risk and benefit is required
with the use of combination immunosuppressive therapy
for refractory autoimmune diseases, the high mortality rate
in patients with autoimmune diseases who experience dis-
ease relapse or fail to standard therapy warrants considera-
tion of the strategy.
In conclusion, the current study was performed using a
more practical approach for ITP patients showing evidence
of H. pylori infection. In H. pylori-associated ITP patients,
the median platelet count at 6 months after treatment and
the response duration in the EI group of patients were supe-
rior to those of the other groups. However, since this study
included only a small number of patients, a further investiga-
tion is required to confirm the findings of this study.
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